Schroders Capital Global Innovation Trust PLC - London-based investment trust with a diversified portfolio of global private and public equity companies - Receives USD5.8 million distribution related to the first milestone of the Kymab sale to Sanofi SA. In April 2021, Schroders Capital Global Innovation completed the sale of its shares in Kymab to Sanofi for initial proceeds of USD87 million. Company says: "At that time, the company explained there was the potential for additional contingent payments of up to USD27 million subject to the achievement of various development and regulatory milestones. This announced payment reflects the first milestone event, with the potential for USD21 million of further contingent payments in the future."

Current stock price: 13.20 pence, up 0.4%

12-month change: down 7.8%

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.